Latest Hotspot

Intellia Launches Phase 3 MAGNITUDE Trial for CRISPR Therapy NTLA-2001 in Cardiac Amyloidosis

22 March 2024
3 min read

Intellia Therapeutics, Inc., a prominent enterprise engaged in the advanced clinical development of gene modification solutions, has reported the commencement of treatment for the inaugural participant within their international, crucial Phase 3 trial named MAGNITUDE, which evaluates the efficacy of their therapeutic candidate NTLA-2001. This endeavor is centered on transforming medical treatments through the application of CRISPR technology.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

NTLA-2001 stands as an experimental gene-editing therapeutic based on in vivo CRISPR technology, tailored to serve as a one-off intervention aimed at disabling the TTR gene, hence obstructing the synthesis of the TTR protein in addressing transthyretin amyloidosis. The clinical study, titled MAGNITUDE, is currently assessing the effectiveness and safety profile of NTLA-2001 in subjects diagnosed with ATTR amyloidosis complicated by cardiomyopathy.

Intellia Therapeutics' top executive, John Leonard, M.D., highlighted the significance of the initiation of patient dosing within the MAGNITUDE study for NTLA-2001, marking a progressive step toward the potential development of a singular gene-editing therapy for those affected by ATTR amyloidosis. 

Dr. Leonard expressed anticipation over the forthcoming insights into NTLA-2001's performance and its safety in treating cardiomyopathy within the crucial Phase 3 clinical trial. He held that favorable results could lay the foundation for subsequent international regulatory submissions, strongly aligned with the company's mission to introduce an innovative treatment to the ATTR amyloidosis patient population.

Julian Gillmore, M.D., Ph.D., an esteemed Medicine Professor at the National Amyloidosis Centre at UCL, affiliated with the Royal Free Hospital in the U.K., and the appointed coordinator for the Phase 3 trial on a national level, conveyed his team’s excitement to be at the forefront in administering NTLA-2001 to a patient. He underscored the potential this in vivo CRISPR-based therapy has to revolutionize care standards for individuals battling this severe illness.

As a ground-breaking therapeutic candidate and the first of its kind, NTLA-2001 targets the deactivation of the gene responsible for producing transthyretin. Promising early stage clinical results from Phase 1 trials suggest that NTLA-2001 has consistently achieved substantial and enduring suppression of transthyretin levels post-treatment.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of March 20 2024, there are 27 investigational drugs for the TTR target, including 25 indications, 44 R&D institutions involved, with related clinical trials reaching 143, and as many as 6792 patents.

NTLA-2001 represents a significant advancement in the field of biomedicine. Its utilization of CRISPR/Cas technology and focus on targeting TTR protein opens up possibilities for treating various diseases within the cardiovascular, nervous system, congenital, and endocrinology and metabolic disease areas. The drug's progression to Phase 3 trials indicates promising results in earlier stages, and its orphan drug status highlights its potential to address unmet medical needs in rare diseases.

图形用户界面, 文本, 应用程序

描述已自动生成

Your Ultimate Guide to Finding Glutathione on Synapse
Drug Insights
2 min read
Your Ultimate Guide to Finding Glutathione on Synapse
22 March 2024
Glutathione, a diminutive molecule drug, is a versatile medication used to treat a diverse range of medical conditions.
Read →
Brenig Therapeutics Presents New LRRK2 Inhibitor Findings for Parkinson's Disease at 2024 ACS Spring Meeting
Latest Hotspot
3 min read
Brenig Therapeutics Presents New LRRK2 Inhibitor Findings for Parkinson's Disease at 2024 ACS Spring Meeting
22 March 2024
During the 2024 ACS Spring Meeting, Brenig Therapeutics showcased novel findings related to their leading LRRK2 inhibitor, which is aimed at tackling Parkinson's disease.
Read →
Eli Lilly Reveals the Crystal Form Patent of FGFR3, Unveiling the Structure of LOXO-435
Hot Spotlight
6 min read
Eli Lilly Reveals the Crystal Form Patent of FGFR3, Unveiling the Structure of LOXO-435
21 March 2024
On March 14, 2024, Eli Lilly unveiled a WO patent for a crystalline salt form of an FGFR3 inhibitor, likely relating to LOXO-435's structure, within the pyrimido[4,5-b]pyrazine compound class.
Read →
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (5)
GPCR Targets and Pipeline at the JP Morgan Healthcare Conference 2024 (5)
21 March 2024
In this article, we will focus on Sosei Heptares, a leading company in the field of GPCR new drug development, and its GPCR research and development pipeline.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.